Natpar (parathyroid hormone): Discontinuation of manufacturing at the end of 2024 and update on 100mcg shortage
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Natpar
|
| Active substance |
parathyroid hormone
|
| Therapeutic area (MeSH) |
Hypoparathyroidism
|
| Procedure number |
EMEA/H/C/003861
|
| Regulatory outcome |
Maintenance
|
| DHPC type |
Medicine shortage
|
| Human ATC code |
H05AA03
|
| Dissemination date |
04/10/2022
|